Effects of Spironolactone on Matrix Metalloproteinases (MMPs) in Heart Failure
Information source: Tottori University Hospital
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Chronic Stable Heart Failure
Intervention: spironolactone + furosemide (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Tottori University Hospital
Summary
The purpose of this study is to evaluate the effects of spironolactone on circulating MMP
levels and insulin resistance in patients with chronic heart failure.
Clinical Details
Official title: Effects of Spironolactone on Circulating MMPs in Patients With Chronic Heart Failure
Study design: Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Crossover Assignment, Efficacy Study
Primary outcome: MMP levels
Detailed description:
Myocardial fibrosis is observed in failing hearts. MMPs are considered markers of fibrosis.
Recently, circulating MMPs can be measured and are elevated in patients with chronic heart
failure (CHF). It has been reported that spironolactone improves myocardial fibrosis in CHF
animal models. Therefore, the purpose of this study is to evaluate the effects of
spironolactone on circulating MMP levels in patients with chronic heart failure.
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- chronic stable heart failure
Locations and Contacts
Additional Information
Starting date: January 2004
Ending date: December 2005
Last updated: April 18, 2008
|
